Propoxyphene-induced torsades de pointes

Heart Rhythm

Volumn 8, Issue 12, 2011, Pages 1952-1954

  Adler, Arnon ^a   Viskin, Sami ^a   Bhuiyan, Zahir A ^b   Eisenberg, Elon ^c   Rosso, Raphael ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Drug induced; Long QT; Torsades de pointes

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DEXTROPROPOXYPHENE; ENALAPRIL; FLUOXETINE; MAGNESIUM; OMEPRADEX; OMEPRAZOLE; PARACETAMOL; POTASSIUM; PRAVASTATIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOKALEMIA; ORTHOPEDIC SURGERY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QT PROLONGATION; SYNCOPE; TORSADE DES POINTES;

AGED; ANALGESICS, OPIOID; DEXTROPROPOXYPHENE; DRUG RECALLS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; TORSADES DE POINTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 82455171908     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2011.07.015     Document Type: Article

References (32)

1. U.S. Food and Drug Administration FDA Drug Safety Communication: FDA recommends against the continued use of propoxyphene. Safety announcement 11-19-2010 http://www.fda.gov/Drugs/DrugSafety/ucm234338.htm Accessed August 27, 2011
2. C.E.R.T. Arizona Center for Education and Reseacrh on Therapeutics Ressources for professionals. QT drug lists by risk groups. Drugs that prolong the QT interval and/or induce torsades de pointes ventricular arrhythmia http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm Accessed August 26, 2011
3. D. Zeltser, D. Justo, A. Halkin, V. Prokhorov, K. Heller, and S. Viskin Torsades de pointes due to noncardiac drugs: most patients have easily identifiable risk factors Medicine (Baltimore) 82 2003 282 290
4. S. Viskin, D. Justo, A. Halkin, and D. Zeltser Long QT syndrome caused by noncardiac drugs Prog Cardiovasc Dis 45 2003 415 427
5. T. Nakajima, Y. Kaneko, M. Manita, T. Iso, and M. Kurabayashi Aborted cardiac arrest in a patient carrying KCNE1 D85N variant during the postpartum period Intern Med 49 2010 1875 1878
6. A.M. Lahtinen, A. Marjamaa, H. Swan, and K. Kontula KCNE1 D85N polymorphisma sex-specific modifier in type 1 long QT syndrome? BMC Med Genet 12 2011 11
7. A.D. Paulussen, R.A. Gilissen, and M. Armstrong Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients J Mol Med 82 2004 182 188
8. Y. Nishio, T. Makiyama, and H. Itoh D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome J Am Coll Cardiol 54 2009 812 819
9. J.C. Hancox, and J.S. Mitcheson Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology Br J Pharmacol 149 2006 457 459
10. S. Rajamani, L.L. Eckhardt, and C.R. Valdivia Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine Br J Pharmacol 149 2006 481 489
11. D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels J Pharmacol Exp Ther 300 2002 543 548
12. H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment Eur J Pain 10 2006 287 333
13. U.S. Food and Drug Administration (FDA) FDA Drug Safely Communication COX-2 selective and non-selective non-steroidal anti-inflammatory drugs NSAIDs. 4-7-2005 http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm151410.htm Accessed August 26, 2011
14. A.M. Schjerning Olsen, E.L. Fosbol, and J. Lindhardsen Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study Circulation 123 2011 2226 2235
15. C. Sticherling, B.A. Schaer, P. Ammann, M. Maeder, and S. Osswald Methadone-induced torsades de pointes tachycardias Swiss Med Wkly 135 2005 282 285
16. D.D. Routhier, K.D. Katz, and D.E. Brooks QTc prolongation and torsades de pointes associated with methadone therapy J Emerg Med 32 2007 275 278
17. L. Pimentel, and D. Mayo Chronic methadone therapy complicated by torsades de pointes: a case report J Emerg Med 34 2008 287 290
18. M.J. Krantz, L. Lewkowiez, H. Hays, M.A. Woodroffe, A.D. Robertson, and P.S. Mehler Torsades de pointes associated with very-high-dose methadone Ann Intern Med 137 2002 501 504
19. D. Atkinson, A. Dunne, and M. Parker Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user Anaesthesia 62 2007 952 955
20. E.C. Pearson, and R.L. Woosley QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system Pharmacoepidemiol Drug Saf 14 2005 747 753
21. The European Agency for the Evaluation of Medicinal Products Evaluation of medicines for human use EMEA public statement of the recommendation to suspend the marketing authorisation for ORLAAM (levacetylmethadol) in the European Union. EMEA/8776/01. London, April 19, 2001 http://www.ema.europa.eu/ docs/en-GB/document-library/Public-statement/2009/12/WC500018335.pdf Accessed August 26, 2011
22. S. Agarwal Clinical pharmacology of propoxyphene Office of Clinical Pharmacology; Center for Drug Evaluation and research. U.S. Food and Drug Administration (FDA) http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/ ucm129260.pdf Accessed August 26, 2011
23. T.N. Andreassen, P. Klepstad, and A. Davies Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients Eur J Clin Pharmacol 67 2011 493 506
24. D.J. Chang, T.D. Kweon, and S.B. Nam Effects of fentanyl pretreatment on the QTc interval during propofol induction Anaesthesia 63 2008 1056 1060
25. R.L. Deamer, D.R. Wilson, D.S. Clark, and J.G. Prichard Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM) J Addict Dis 20 2001 7 14
26. C.B. Eap, S. Crettol, and J.S. Rougier Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers Clin Pharmacol Ther 81 2007 719 728
27. S. Fanoe, G.B. Jensen, P. Sjogren, M.P. Korsgaard, and M. Grunnet Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro Br J Clin Pharmacol 67 2009 172 179
28. A.N. Katchman, K.A. McGroary, and M.J. Kilborn Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents J Pharmacol Exp Ther 303 2002 688 694
29. C. Ulens, P. Daenens, and J. Tytgat Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents Cardiovasc Res 44 1999 568 578
30. E.F. Wedam, G.E. Bigelow, R.E. Johnson, P.A. Nuzzo, and M.C. Haigney QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial Arch Intern Med 167 2007 2469 2475
31. B.J. Zunkler, and M. Wos-Maganga Comparison of the effects of methadone and heroin on human ether-a-go-go-related gene channels Cardiovasc Toxicol 10 2010 161 165
32. S. Viskin, and U. Rosovski The degree of potassium channel blockade and the risk of torsades de pointes: the truth, nothing but the truth, but not the whole truth Eur Heart J 26 2005 536 537